| (in millions, except per share data) | Quarter Ended June 30, 2025 | Full-Year Ended December 31, 2025 | |||||||||||||||||||||||||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
| Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q2 2025 acquired IPR&D and milestones expense | $ | — | $ | 3.26 | $ | 3.30 | $ | 248 | $ | 12.09 | $ | 12.29 | |||||||||||||||||||||||
| Q2 2025 acquired IPR&D and milestones expense | 823 | (0.42) | (0.42) | 823 | (0.42) | (0.42) | |||||||||||||||||||||||||||||
Guidance including Q2 2025 acquired IPR&D and milestones expensea | $ | 823 | $ | 2.84 | $ | 2.88 | $ | 1,071 | $ | 11.67 | $ | 11.87 | |||||||||||||||||||||||